Humana Inc. (NYSE:HUM) Shares Sold by Sanibel Captiva Trust Company Inc.

Sanibel Captiva Trust Company Inc. lowered its stake in shares of Humana Inc. (NYSE:HUM) by 45.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,745 shares of the insurance provider’s stock after selling 1,467 shares during the period. Sanibel Captiva Trust Company Inc.’s holdings in Humana were worth $443,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the company. Atlas Brown Inc. increased its holdings in shares of Humana by 0.6% in the fourth quarter. Atlas Brown Inc. now owns 6,352 shares of the insurance provider’s stock valued at $1,611,000 after buying an additional 38 shares in the last quarter. Moors & Cabot Inc. boosted its position in Humana by 2.5% during the 3rd quarter. Moors & Cabot Inc. now owns 1,639 shares of the insurance provider’s stock worth $519,000 after acquiring an additional 40 shares during the period. OLD National Bancorp IN lifted its position in shares of Humana by 1.8% in the third quarter. OLD National Bancorp IN now owns 2,613 shares of the insurance provider’s stock worth $828,000 after purchasing an additional 45 shares in the last quarter. Your Advocates Ltd. LLP boosted its holdings in shares of Humana by 81.8% during the third quarter. Your Advocates Ltd. LLP now owns 100 shares of the insurance provider’s stock worth $32,000 after purchasing an additional 45 shares during the period. Finally, Brooklyn Investment Group increased its stake in Humana by 6.7% in the 3rd quarter. Brooklyn Investment Group now owns 736 shares of the insurance provider’s stock valued at $233,000 after buying an additional 46 shares during the period. Institutional investors and hedge funds own 92.38% of the company’s stock.

Insider Activity

In other Humana news, insider Timothy S. Huval sold 3,703 shares of the firm’s stock in a transaction dated Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total transaction of $948,930.78. Following the completion of the transaction, the insider now owns 8,181 shares in the company, valued at $2,096,463.06. This trade represents a 31.16 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.29% of the stock is owned by company insiders.

Humana Stock Up 2.5 %

HUM stock opened at $282.63 on Monday. Humana Inc. has a twelve month low of $213.31 and a twelve month high of $415.73. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.67. The company has a market cap of $34.03 billion, a PE ratio of 25.03, a price-to-earnings-growth ratio of 2.02 and a beta of 0.55. The business’s 50-day simple moving average is $273.81 and its 200 day simple moving average is $307.57.

Humana (NYSE:HUM) last announced its quarterly earnings data on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share for the quarter, topping the consensus estimate of $3.48 by $0.68. The company had revenue of $29.30 billion for the quarter, compared to analyst estimates of $28.66 billion. Humana had a return on equity of 13.20% and a net margin of 1.18%. On average, research analysts anticipate that Humana Inc. will post 16.14 earnings per share for the current year.

Humana Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Tuesday, December 31st will be issued a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.25%. The ex-dividend date is Tuesday, December 31st. Humana’s payout ratio is 31.36%.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on HUM shares. KeyCorp began coverage on shares of Humana in a report on Friday, October 11th. They set a “sector weight” rating on the stock. Deutsche Bank Aktiengesellschaft lowered their target price on Humana from $349.00 to $250.00 and set a “hold” rating on the stock in a research note on Thursday, October 3rd. Leerink Partners downgraded Humana from an “outperform” rating to a “market perform” rating and cut their price target for the stock from $400.00 to $250.00 in a research note on Wednesday, October 2nd. Morgan Stanley boosted their price target on Humana from $288.00 to $301.00 and gave the company an “equal weight” rating in a research note on Tuesday, December 17th. Finally, Wells Fargo & Company cut their price objective on shares of Humana from $387.00 to $290.00 and set an “overweight” rating on the stock in a research report on Monday, November 4th. Twenty equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $302.70.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.